REMEGEN1月14日,荣昌生物(688331.SH/09995.HK)宣布:注射用泰它西普治疗眼肌型重症肌无力(OMG)的国内Ⅲ期临床研究,已完成首例患者入组给药。2025年5月,泰它西普治疗全身型重症肌无力(gMG)已在国内获批上市。泰它西普这项治疗OMG的多中心、随机、双盲、安慰剂对照的Ⅲ期临床研究,计划纳入120例受试者。试验分为筛选期和双盲治疗期,经筛选合格的受试者按照1:1的比例随机...
Source LinkREMEGEN1月14日,荣昌生物(688331.SH/09995.HK)宣布:注射用泰它西普治疗眼肌型重症肌无力(OMG)的国内Ⅲ期临床研究,已完成首例患者入组给药。2025年5月,泰它西普治疗全身型重症肌无力(gMG)已在国内获批上市。泰它西普这项治疗OMG的多中心、随机、双盲、安慰剂对照的Ⅲ期临床研究,计划纳入120例受试者。试验分为筛选期和双盲治疗期,经筛选合格的受试者按照1:1的比例随机...
Source LinkDisclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.